Pfizer 2006 Annual Report Download - page 18

Download and view the complete annual report

Please find page 18 of the 2006 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 84

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84

Revenues—Major Pharmaceutical Products
Revenue information for several of our major Pharmaceutical products follow:
(MILLIONS OF DOLLARS) YEAR ENDED DEC. 31, % CHANGE
_____________________________________ ________________
PRODUCT PRIMARY INDICATIONS 2006 2005 2004 06/05 05/04
Cardiovascular and
metabolic diseases:
Lipitor Reduction of LDL cholesterol $12,886 $12,187 $10,862 6 12
Norvasc Hypertension 4,866 4,706 4,463 3 5
Cardura Hypertension/Benign prostatic hyperplasia 538 586 628 (8) (7)
Caduet Reduction of LDL cholesterol and hypertension 370 185 50 99 272
Accupril/Accuretic Hypertension/Congestive heart failure 266 294 665 (10) (56)
Chantix/Champix Smoking cessation 101 ——* —
Central nervous
system disorders:
Zoloft Depression and certain anxiety disorders 2,110 3,256 3,361 (35) (3)
Lyrica Epilepsy, post-herpetic neuralgia and diabetic
peripheral neuropathy 1,156 291 13 297 M+
Geodon/Zeldox Schizophrenia and acute manic or mixed episodes
associated with bipolar disorder 758 589 467 29 26
Neurontin Epilepsy and post-herpetic neuralgia 496 639 2,723 (22) (77)
Aricept
(a)
Alzheimer’s disease 358 346 308 4 12
Xanax/Xanax XR Anxiety/Panic disorders 316 409 378 (23) 8
Relpax Migraine headaches 286 233 169 23 38
Arthritis and pain:
Celebrex Arthritis pain and inflammation, acute pain 2,039 1,730 3,302 18 (48)
Infectious and respiratory
diseases:
Zyvox Bacterial infections 782 618 463 27 33
Zithromax/Zmax Bacterial infections 638 2,025 1,851 (69) 9
Vfend Fungal infections 515 397 287 30 38
Diflucan Fungal infections 435 498 945 (13) (47)
Urology:
Viagra Erectile dysfunction 1,657 1,645 1,678 1 (2)
Detrol/Detrol LA Overactive bladder 1,100 988 904 11 9
Oncology:
Camptosar Metastatic colorectal cancer 903 910 554 — 64
Aromasin Breast cancer 320 247 143 30 73
Ellence Breast cancer 312 367 344 (15) 7
Sutent Advanced and/or metastatic
renal cell carcinoma (mRCC) and refractory
gastrointestinal stromal tumors (GIST) 219 ——*—
Ophthalmology:
Xalatan/Xalacom Glaucoma and ocular hypertension 1,453 1,372 1,227 6 12
Endocrine disorders:
Genotropin Replacement of human growth hormone 795 808 736 (2) 10
All other:
Zyrtec/Zyrtec-D Allergies 1,569 1,362 1,287 15 6
Alliance revenue Alzheimer’s disease (Aricept), neovascular (wet)
age-related macular degeneration (Macugen),
Parkinson’s disease (Mirapex), hypertension
(Olmetec), multiple sclerosis (Rebif) and chronic
obstructive pulmonary disease (Spiriva) 1,374 1,065 721 29 48
(a)
Represents direct sales under license agreement with Eisai Co., Ltd.
M+ Change greater than 1,000%.
* Calculation not meaningful.
16 2006 Financial Report
Financial Review
Pfizer Inc and Subsidiary Companies